MIRA INFORM REPORT

 

 

Report Date :

07.02.2014

 

IDENTIFICATION DETAILS

 

Name :

STANLEY PHARMACEUTICALS (PVT.) LIMITED (SPPL)

 

 

Registered Office :

Plot 84-B Hayatabad Industrial Estate, Jamrud Road, Peshawar

 

 

Country :

Pakistan

 

 

Financials (as on) :

30.06.2013

 

 

Date of Incorporation :

15.01.1996

 

 

Legal Form :

Private Limited Company

 

 

Line of Business :

Manufacturing of Pharmaceutical products

 

 

No. of Employees :

80

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

No complaints

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – September 30, 2013

 

Country Name

Previous Rating

(30.06.2013)

Current Rating

(30.09.2013)

Pakistan

B2

B2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

PAKISTAN - ECONOMIC OVERVIEW

 

Decades of internal political disputes and low levels of foreign investment have led to slow growth and underdevelopment in Pakistan. Agriculture accounts for more than one-fifth of output and two-fifths of employment. Textiles account for most of Pakistan's export earnings, and Pakistan's failure to expand a viable export base for other manufactures has left the country vulnerable to shifts in world demand. Official unemployment is under 6%, but this fails to capture the true picture, because much of the economy is informal and underemployment remains high. Over the past few years, low growth and high inflation, led by a spurt in food prices, have increased the amount of poverty - the UN Human Development Report estimated poverty in 2011 at almost 50% of the population. Inflation has worsened the situation, climbing from 7.7% in 2007 to almost 12% for 2011, before declining to 10% in 2012. As a result of political and economic instability, the Pakistani rupee has depreciated more than 40% since 2007. The government agreed to an International Monetary Fund Standby Arrangement in November 2008 in response to a balance of payments crisis. Although the economy has stabilized since the crisis, it has failed to recover. Foreign investment has not returned, due to investor concerns related to governance, energy, security, and a slow-down in the global economy. Remittances from overseas workers, averaging about $1 billion a month since March 2011, remain a bright spot for Pakistan. However, after a small current account surplus in fiscal year 2011 (July 2010/June 2011), Pakistan's current account turned to deficit in fiscal year 2012, spurred by higher prices for imported oil and lower prices for exported cotton. Pakistan remains stuck in a low-income, low-growth trap, with growth averaging about 3% per year from 2008 to 2012. Pakistan must address long standing issues related to government revenues and energy production in order to spur the amount of economic growth that will be necessary to employ its growing and rapidly urbanizing population, more than half of which is under 22. Other long term challenges include expanding investment in education and healthcare, adapting to the effects of climate change and natural disasters, and reducing dependence on foreign donors.

 

Source : CIA

 


company name

 

STANLEY PHARMACEUTICALS (Pvt.) LIMITED (SPPL)

 

 

GENERAL INFORMATION

 

Business Name

STANLEY PHARMACEUTICALS (PVT.) LIMITED (SPPL)

Address

Registered Address:

Plot 84-B Hayatabad Industrial Estate,Jamrud Road, Peshawar

Telephone

(+92) (91) 5817468

(+92)(91) 5817469

Fax

(+92) (91) 5818963

Email

corporate@rafaqatbabar.com

Website

www.stanleypharma.com

Business activities

Manufacturing of Pharmaceutical products

 

Registry Details

CRO Registration Number

0036045

Date of Registration

January 15, 1996

           

Other registry & certification details:

Current Legal Form

Private Limited Company

National Tax Registration Number

0709000-5

Date of Registration

July 06, 1996

GST Registration Number

0501300401455

Date of Registration

November 10, 1997

Chamber of Commerce & Industry

Peshawar Chamber of Commerce & Industries

ISO Certification

Undetermined

Other certifications

Undetermined

 

Capital

Type

No. of Shares

Par Value

Total Value

Authorized

100,000

100

10,000,000

Issued, Subscribed & Paid-Up

100,000

100

10,000,000

 

History

Who started

Mr. Tilla Muhammad

When started

January 15, 1996

Change in management

None

Year of change

N/A

Change in legal status

None

Year of change

N/A

Change in business name

None

Year of change

N/A

 

 

PRINCIPALS (SPONSORS)

 

Name

Number of Shares

Nationality

Appointment Date (Last)

Mr. Zia Muhammad

        20,268

Pakistani

October 31, 2011

Mr. Tilla Muhammad

        17,727

Pakistani

October 31, 2011

Mr. Riaz Muhammad

        17,727

Pakistani

October 31, 2011

 

Other share holder

 

 

Mrs. Shehnaz

15,606

 

Mrs. Nagina Riaz

15,606

 

Mrs. Nagina Zia

13,066

 

Total

100,000

 

 

 

KEY MANAGEMENT

 

Name

 

Position in organization

Qualification

Years in employment

Mr. Tilla Muhammad

Chief Executive Officer

Undetermined

Undetermined

Mr. Zia Muhammad

Managing Director

Master

Undetermined

 

Statutory offices

Name of service provider

Statutory Auditors

M/s. Rafaqat Babar & Co

Chartered Accountants

Legal Advisory Services

 Ms. Sherin Khan

 

 

BANKERS

 

Bank name

Approved financing limits PKR

Habib Bank Ltd

Rs. 24,520,547

Habib Bank Ltd

Rs. 20,000,000

Habib Bank Ltd

Rs. 3,161,250

Bank Alfalah Ltd

Depository relation

NIB Bank Limited

Depository relation

 

 


DETAILS OF BUSINESS ACTIVITIES

 

The core business focus of SPPL is manufacturing of pharmaceutical products.

 

Products:

                                   

Top of Form

Analgesics, Antipyretics, Nsaids, Antigout, And Antirheumatics (Category - 2) Bottom of Form

Fenbro

Kamic

Pedrol

Pedrol Extra

Pedrol Fort

Pedrol Total

Rid-All

Rid-All Forte

Sanid

 

 

 

Anti-Allergics (Antihistamines) And Drugs Used In Anaphylaxis (Category - 3)

Lorid

Stenzar

 

 

Anti-Infective Drugs (Category - 6)

Bendazol

Naxid

Riam

Ridox

Uran

 

 

 

Drugs Affecting The Blood (Category - 10)

F.S

Ferfolic

 

 

Gastrointestinal Drugs (Category - 17)

Dymin

Furamid

Manacid

Manacid Forte

Perl

 

 

 

Hormones And Other Endocrine Drugs And Contraceptives (Category - 18)

Hex

 

 

 

Ophthalmological Preparations (Category - 21)

Rozid

 

 

 

Obstetrics And Gynecological Preparations (Category - 22)

Clozim-1

Clozim-6

 

 

Drugs Acting On The Respiratory Tract (Category - 25)

Broxol

Broxol-Dm

Flunec-D

Pedrol-Cf

Phyline Syrup

Rintal

 

 

Vitamins, Minerals, Tonics, And Other Substances (Category - 27)

Calsid

Fervit

Multonic

Vasedex-C

Vasedex-L

Veril Bottom of Form

 

 

 

Purchases (Incl. Imports)

Imports from

UK, Italy, USA

Importing terms

L/C

Local

All over Pakistan

Local buying terms

Cash and Credit of 30-45 days

 

Sales (Incl. Exports)

Exports to

Afghanistan

Exporting terms

N/A

Local

(All over Pakistan)

Local selling terms

Cash and Credit of 45-60 Days

 

 

NUMBER OF EMPLOYEES

 

Nature of employment

Current Year

Previous Year

All Staff

80

80

Total

80

80

 

 

BUSINESS FACILITIES

 

Head office Address

Owned / Rented

Area (approx.)

84-B Hayatabad Industrial Estate Jamrud Road Peshawar

Leased

Undetermined

Factory Address

Owned / Rented

Area (approx.)

84-B Hayatabad Industrial Estate Jamrud Road Peshawar

Leased

Undetermined

 


MARKET REPUTATION

 

2 buyers were contacted to get a feedback about SPPL and its products. All the feedback was found Satisfactory and no disputes or untoward events including complaints about quality of products were reported/ identified during inquiry.

 

 

DETAILS OF RELATED BUSINESSES

 

Business Name

City

Line of Business

Percentile of Shareholding

Undetermined

 

 

BUSINESS PERFORMANCE

 

Particulars

30-Jun-13

30-Jun-12

 % Change

 

 

 

 

Current assets

         73,863,715

        64,786,441

        14.01

Current liabilities

         56,862,125

        55,889,305

          1.74

Working capital

          17,001,590

          8,897,136

        91.09

 

 

 

 

Non-current assets

         62,666,326

        63,074,004

        (0.65)

Long term liabilities

           7,261,320

          8,283,330

       (12.34)

Net worth

          55,405,006

        54,790,674

          1.12

 

 

 

 

Turnover

       463,641,515

      443,571,587

          4.52

Gross Profit

        135,805,869

       130,480,339

          4.08

EBIT

         16,452,588

        16,029,499

          2.64

Profit / (Loss) before tax

         11,880,510

        11,707,979

          1.47

Statutory Provision

              843,516

                    -  

 

Provision for taxation

           2,318,208

                    -  

 

Profit / (Loss) after tax

            8,718,786

        11,707,979

      (25.53)

Creditors

         41,653,554

        30,481,533

         36.65

Stock in Trade

         27,588,169

        30,986,771

      (10.97)

Cash & bank balances

         12,556,173

          5,024,585

       149.89

Advanced, Deposit & Prepayments

         33,470,022

        28,625,691

16.92

Growth trend

 

 

 

Sales growth (%)

4.52%

 

 

Gross profit growth (%)

4.08%

 

 

 

 

 

 

Solvency

 

 

 

Current ratio

                  1.30

                 1.16

 

Quick ratio

                  1.29

                 1.16

 

Total liabilities to net worth ratio (%)

               115.74

              117.12

 

 

 

 

 

Profitability

 

 

 

Return on sales (%)

                  1.88

                 2.64

 

Return on net worth (%)

                 15.74

                21.37

 

 

 

 

 

 

 

INTERVIEW & REPORTER COMMENTS

 

Contact person

Mr. Abdullah

Position

Admin Manager

Contact Person Comments

Mr. Abdullah confirmed business operations, business information and shared financial information.    

Analyst’s Observations/ comments

The office comprised of fourteen air-conditioned rooms, with fifteen computers and average office furniture.

Sixty to Seventy employees were present in the office premises at the time of physical visit.

Different Pharmaceutical Products were observed at site. 

SPPL have employed skilled and educated staff working for the company.

The concern have installed the latest machinery for the production of its product hence producing quality products.

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.62.50

UK Pound

1

Rs.101.92

Euro

1

Rs.84.50

 

 

INFORMATION DETAILS

 

Report Prepared by :

NNA

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.